Promoter holding
64.27%
BG
Bliss Gvs Pharma Limited - Due diligence report
A 360° intelligence report on Bliss Gvs Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signa…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Bliss Gvs Pharma — 360° Intelligence Report
Generated from MCA filings & public records80/100
Trust Score
Low Risk
Bliss Gvs Pharma is assessed as Low Risk with a Trust Score of 80/100. Bliss Gvs Pharma is an active public limited indian non-government company incorporated in 1984, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.
Report generated on 17 Jul 2026 from the latest processed filings. Bliss Gvs Pharma Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
80/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
48/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (BB+).
Charges position: 5 open (261.00 cr) · 18 satisfied (301.25 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 6 | 48.0 cr |
| Standard Chartered Bank | 1 | 48.0 cr |
| Idbi Trusteeship Services Limited | 1 | 48.0 cr |
| State Bank Of Bikaner & Jaipur | 1 | 48.0 cr |
| Firstrand Bank Limited | 1 | 48.0 cr |
| Punjab National Bank | 1 | 48.0 cr |
Compliance Score: 48/100 Caution Indicated
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Flagged by authority: DSE, BSE.
- Litigation present in 2 court forum(s).
- Delayed payments to MSME suppliers disclosed (58 disclosure(s)).
- 2 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| VIBHA GAGAN SHARMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SANTOSH LAXMAN PARAB | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NANDKUMAR KASHINATH CHODANKAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DEEPAK BHALCHANDRA SAWANT | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHILPA BHATIA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHRUTI VISHAL RAO | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Aditi Himanshu Bhatt | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Narsimha Shibroor Kamath | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 8 directors on the board.
- No disqualified or deactivated DINs.
- 1 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2025)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
1
Group entities
1
Capital events
7 allotment(s) · 0 transfer(s)
Promoters hold the largest single block of equity - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Asterisk Lifesciences Ltd. | Subsidiary Company | 74.00% |
| Bliss Gvs International Pte. Ltd. | Subsidiary Company | 74.00% |
| Kremoint Pharma Pvt. Ltd. | Subsidiary Company | 74.00% |
Key managerial personnel: VIBHA GAGAN SHARMA (Whole-time director) · DEEPAK BHALCHANDRA SAWANT (CFO) · SHRUTI VISHAL RAO (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 80 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +2.1x over 4 year(s).
Profit expanded 24% year-on-year.
Net margin improved to 0.86.
EPFO headcount growing - hiring signal.
Operating for 41+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Compliance score is weak (48/100).
5 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 57.52 Lakh.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence70/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment83/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 5 open charge(s) of 261.00 cr already registered.
- Compliance gaps should be priced into terms.
Investor view85/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 4 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events10 Oct 2025
Director appointed
Narsimha Shibroor Kamath (Ceo)
31 Jul 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
24 Jul 2024
Director ceased
NANDKUMAR KASHINATH CHODANKAR
22 Jun 2024
Director appointed
NANDKUMAR KASHINATH CHODANKAR (Director)
16 Dec 2023
Charge created
Others - 35.00 cr
02 Sep 2023
Charge created
Others - 75.00 cr
28 Mar 2023
Charge satisfied
Others
30 Dec 2022
Director appointed
DEEPAK BHALCHANDRA SAWANT (CFO)
23 Nov 2022
Securities allotted
267750 Equity Shares - 1.15 cr raised
15 Sep 2022
Securities allotted
76750 Equity Shares - 33.00 Lakh raised
22 Aug 2022
Director ceased
ADITI HIMANSHU BHATT
16 Jun 2022
Securities allotted
46000 Equity Shares - 19.78 Lakh raised
09 May 2022
Securities allotted
84250 Equity Shares - 36.23 Lakh raised
18 Nov 2021
Securities allotted
169000 Equity Shares - 72.67 Lakh raised
10
Key Observations
Auto-generated from the data aboveRevenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - manageable leverage.
Net worth is positive.
8 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of BB+ from Crisil.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold the largest single block of equity as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 7 security allotment(s) - amounts available in the full report.
23 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Sree Rayalaseema Hi-Strength H | L24110AP2005PLC045726 | Kurnool Dist, Andhra Pradesh, India |
| Transpek | L23205GJ1965PLC001343 | Vadodara, Gujarat, India |
| Yasho Industries | L74110MH1985PLC037900 | Mumbai, Maharashtra, India |
| Kanoria Chemicals & Industries | L24110WB1960PLC024910 | Kolkata, West Bengal, India |
| Swaraj | U01409PN2010PLC137013 | Phaltan, Maharashtra, India |
| Supriyalifescience | L51900MH2008PLC180452 | Mumbai, Maharashtra, India |
| Sbl Energy Limited | U24292CT2002PLC015581 | Raipur, Chattisgarh, India |
| Karthik Agro Industries Private Limited | U15323KA2007PTC041485 | Bagalkot, Karnataka, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Bliss Gvs Pharma before audits and certifications: compliance score 48/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Bliss Gvs Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 80/100, margin trends, ownership structure and peer set for Bliss Gvs Pharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 80/100, distress signals and MSME payment-delay disclosures - know whether Bliss Gvs Pharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Bliss Gvs Pharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Bliss Gvs Pharma an active company?
Bliss Gvs Pharma has MCA status “Active” with a compliance score of 48/100 (Caution Indicated).
Is Bliss Gvs Pharma financially healthy?
Bliss Gvs Pharma has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Bliss Gvs Pharma?
Its overall Trust Score is 80/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Bliss Gvs Pharma?
Promoters hold the largest single block of equity - exact percentages are in the full report. 8 active director(s) are on record.
Does Bliss Gvs Pharma have loans or charges against its assets?
5 open charge(s) are registered against its assets, and 18 earlier charge(s) stand satisfied.
Is Bliss Gvs Pharma up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 48/100 (Caution Indicated).
Is it risky to lend to Bliss Gvs Pharma?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
